Abbott Laboratories (ABT) Gains from Investment Securities (2009 - 2026)

Abbott Laboratories has disclosed Gains from Investment Securities across 18 years of filings, most recently posting -$34.0 million for Q1 2026.

• Gains from Investment Securities for Q1 2026 came in at -$34.0 million, down 325.0% year-over-year; the trailing twelve-month figure through Mar 2026 was -$44.0 million (down 102.56% YoY), and the FY2025 annual result was -$18.0 million, down 101.04% from the prior year.
• Gains from Investment Securities came in at -$34.0 million for Q1 2026 at Abbott Laboratories, down from $28.0 million in the prior quarter.
• In the past five years, Gains from Investment Securities ranged from a high of $1.9 billion in Q4 2022 to a low of -$51.0 million in Q2 2022.
• The 5-year median for Gains from Investment Securities is -$3.0 million (2022), against an average of $219.6 million.
• Peak annual rise in Gains from Investment Securities reached 86700.0% in 2024, while the deepest fall reached 4700.0% in 2024.
• Abbott Laboratories' Gains from Investment Securities stood at $1.9 billion in 2022, then tumbled by 100.11% to -$2.0 million in 2023, then soared by 86700.0% to $1.7 billion in 2024, then slumped by 98.38% to $28.0 million in 2025, then tumbled by 221.43% to -$34.0 million in 2026.
• The last three Gains from Investment Securities figures came in at -$34.0 million (Q1 2026), $28.0 million (Q4 2025), and -$38.0 million (Q3 2025), per Business Quant data.